Serum pepsinogen levels and OLGA/OLGIM staging in the assessment of atrophic gastritis types

Koç, Deniz Öğütmen; Bektaş, Sibel

doi:10.1136/postgradmedj-2020-139183

Cited by 10 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pepsinogen serology and APCA are also useful in the follow-up of AIG 111. Pepsinogen serology may differentiate autoimmune from H. pylori gastritis, also providing useful information on the clinical profiling of the most advanced atrophic stages 112. Serum pepsinogens are useful for detecting AIG in patients affected by autoimmune thyroiditis 113.…”

Section: Wg 2: Diagnosticsmentioning

confidence: 99%

Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report

Malfertheiner

Mégraud

Rokkas

et al. 2022

Gut

700

842

View full text Add to dashboard Cite

Helicobacter pyloriInfection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management.The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered.Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.

show abstract

Section: Wg 2: Diagnosticsmentioning

confidence: 99%

Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report

Malfertheiner

Mégraud

Rokkas

et al. 2022

Gut

700

842

View full text Add to dashboard Cite

show abstract

“…Another feature is a consistent team of skilled endoscopists and a standardized biopsy protocol, particularly with endoscopists, histopathologists, investigators and patients blinded to the evaluation. Also, the primary outcome was assessed by combination of serum pepsinogen levels and OLGA/OLGIM stage[ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Yiwei Xiaoyu granules for treatment of chronic atrophic gastritis with deficiency syndrome of the spleen and stomach

Chen,

Fan,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND The Correa sequence, initiated by Helicobacter pylori (H. pylori ), commonly progresses to gastric cancer through the stage of chronic atrophic gastritis (CAG). Although eradication of H. pylori only reduces the risk of gastric cancer, it does not eliminate the risk for neoplastic progression. Yiwei Xiaoyu granules (YWXY) are a commonly used composite preparation in Chinese clinics. However, the pursuit of excellence in clinical trials and the establishment of standardized animal experiments are still needed to contribute to full understanding and application of traditional Chinese medicine in the treatment of CAG. AIM To demonstrate the effectiveness of YWXY in patients with CAG and spleen-stomach deficiency syndrome (DSSS), by alleviating histological scores, improving response rates for pathological lesions, and achieving clinical efficacy in relieving DSSS symptoms. METHODS We designed a double-blind, randomized, controlled trial. The study enrolled seventy-two H. pylori -negative patients (mean age, 52.3 years; 38 men) who were randomly allocated to either the treatment group or control group in a 1:1 ratio, and treated with 15 g YWXY or 0.36 g Weifuchun (WFC) tablet combined with the respective dummy for 24 wk. The pre-randomization phase resulted in the exclusion of 72 patients: 50 participants did not meet the inclusion criteria, 12 participants declined to participate, and 10 participants were excluded for various other reasons. Seven visits were conducted during the study, and histopathological examination with target endoscopic biopsy of narrow-band imaging was requested before the first and seventh visits. We also evaluated endoscopic performance scores, total symptom scores, serum pepsinogen and gastrin-17. RESULTS Six patients did not complete the trial procedures. Treatment with YWXY improved the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stage, compared with WFC (P < 0.05). YWXY provided better relief from symptoms of DSSS and better improvement in serum gastric function, compared with WFC (P < 0.05). CONCLUSION YWXY compared with WFC significantly reduced the risk of mild or moderate atrophic disease, according to OLGIM stage, significantly relieved symptoms of DSSS, and improved serum gastric function.

show abstract

“…Several studies have shown that measuring serum levels of PGI, PGII, G17 and anti-H. pylori antibodies can be used to diagnose atrophic gastritis and intestinal metaplasia [36][37][38][39]. A study from Turkey showed that the PG1/PG2 ratio may be useful to identify both autoimmune and environmental atrophic gastritis [40]. A Japanese group showed that high G17 and low PG I/II ratios could be used to identify AIG in a cross-sectional cohort of patients undergoing upper endoscopy [41].…”

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of Autoimmune Gastritis in Patients with a Gastric Precancerous Lesion

Guo,

Schreurs,

Marijnissen

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Autoimmune gastritis (AIG), characterized with the presence of anti-parietal-cell antibodies (APCA), is a risk factor for gastric cancer. However, AIG may go underdiagnosed, especially in the case of H. pylori infection and the presence of gastric precancerous lesions (GPL), due to the ambiguous pathology and delayed symptom onset. Aim: Investigate the prevalence and characteristics of AIG in GPL patients. Methods: Prevalence of AIG was determined with the presence of APCA in patients with GPL (n = 256) and the control group (n = 70). Pathological characteristics and levels of gastrin 17 (G17), pepsinogen (PG) I and II and anti-Helicobacter pylori IgG were assessed in GPL cases, and the severity of intestinal metaplasia and gastric atrophy was scored by expert pathologists. Results: APCA positivity was observed in 18% of cases vs. 7% of controls (p = 0.033). Only 3/256 patients were previously diagnosed with AIG. The presence of APCA was associated with corpus-limited and extended GPL. A receiver operating curve analysis demonstrated that the G17 and PGI/II ratio could identify APCA-positive patients within GPL cases (AUC: 0.884). Conclusions: The prevalence of AIG is higher in patients with GPL but goes undiagnosed. Using G17 and PG I/II as diagnostic markers can help to identify patients with AIG and improve surveillance programs for patients with GPL.

show abstract

Serum pepsinogen levels and OLGA/OLGIM staging in the assessment of atrophic gastritis types

Cited by 10 publications

References 25 publications

Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report

Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report

Yiwei Xiaoyu granules for treatment of chronic atrophic gastritis with deficiency syndrome of the spleen and stomach

Increased Prevalence of Autoimmune Gastritis in Patients with a Gastric Precancerous Lesion

Contact Info

Product

Resources

About